Joshua Demb1,2,3, Linn Abraham4, Diana L Miglioretti4,5, Brian L Sprague6, Ellen S O'Meara4, Shailesh Advani2,3, Louise M Henderson7, Tracy Onega8, Diana S M Buist4, John T Schousboe9, Louise C Walter10, Karla Kerlikowske1,10, Dejana Braithwaite2,3. 1. Department of Epidemiology and Biostatistics. 2. University of California, San Francisco, San Francisco. 3. Department of Oncology, Georgetown University, Washington, DC. 4. Kaiser Permanente Washington Health Research Institute, Seattle. 5. Department of Public Health Sciences, School of Medicine, University of California, Davis, Davis, CA. 6. Department of Surgery, University of Vermont College of Medicine, Burlington, VT. 7. Department of Radiology, University of North Carolina at Chapel Hill, NC. 8. Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, NH. 9. Park Nicollet Clinic & Health Partners Institute, Bloomington, MN. 10. Department of Medicine.
Abstract
BACKGROUND: Potential benefits of screening mammography among women ages 75 years and older remain unclear. METHODS: We evaluated 10-year cumulative incidence of breast cancer and death from breast cancer and other causes by Charlson Comorbidity Index (CCI) and age in the Medicare-linked Breast Cancer Surveillance Consortium (1999-2010) cohort of 222 088 women with no less than 1 screening mammogram between ages 66 and 94 years. RESULTS: During median follow-up of 107 months, 7583 were diagnosed with invasive breast cancer and 1742 with ductal carcinoma in situ; 471 died from breast cancer and 42 229 from other causes. The 10-year cumulative incidence of invasive breast cancer did not change with increasing CCI but decreased slightly with age: ages 66-74 years (CCI0 = 4.0% [95% CI = 3.9% to 4.2%] vs CCI ≥ 2 = 3.9% [95% CI = 3.5% to 4.3%]); ages 75-84 years (CCI0 = 3.7% [95% CI = 3.5% to 3.9%] vs CCI ≥ 2 = 3.4% [95% CI = 2.9% to 3.9%]); and ages 85-94 years (CCI0 = 2.7% [95% CI = 2.3% to 3.1%] vs CCI ≥ 2 = 2.1% [95% CI = 1.3% to 3.0%]). The 10-year cumulative incidence of other-cause death increased with increasing CCI and age: ages 66-74 years (CCI0 = 10.4% [95% CI = 10.3 to 10.7%] vs CCI ≥ 2 = 43.4% [95% CI = 42.2% to 44.4%]), ages 75-84 years (CCI0 = 29.8% [95% CI = 29.3% to 30.2%] vs CCI ≥ 2 = 61.7% [95% CI = 60.2% to 63.3%]), and ages 85 to 94 years (CCI0 = 60.3% [95% CI = 59.1% to 61.5%] vs CCI ≥ 2 = 84.8% [95% CI = 82.5% to 86.9%]). The 10-year cumulative incidence of breast cancer death was small and did not vary by age: ages 66-74 years = 0.2% (95% CI = 0.2% to 0.3%), ages 75-84 years = 0.29% (95% CI = 0.25% to 0.34%), and ages 85 to 94 years = 0.3% (95% CI = 0.2% to 0.4%). CONCLUSIONS: Cumulative incidence of other-cause death was many times higher than breast cancer incidence and death, depending on comorbidity and age. Hence, older women with increased comorbidity may experience diminished benefit from continued screening.
BACKGROUND: Potential benefits of screening mammography among women ages 75 years and older remain unclear. METHODS: We evaluated 10-year cumulative incidence of breast cancer and death from breast cancer and other causes by Charlson Comorbidity Index (CCI) and age in the Medicare-linked Breast Cancer Surveillance Consortium (1999-2010) cohort of 222 088 women with no less than 1 screening mammogram between ages 66 and 94 years. RESULTS: During median follow-up of 107 months, 7583 were diagnosed with invasive breast cancer and 1742 with ductal carcinoma in situ; 471 died from breast cancer and 42 229 from other causes. The 10-year cumulative incidence of invasive breast cancer did not change with increasing CCI but decreased slightly with age: ages 66-74 years (CCI0 = 4.0% [95% CI = 3.9% to 4.2%] vs CCI ≥ 2 = 3.9% [95% CI = 3.5% to 4.3%]); ages 75-84 years (CCI0 = 3.7% [95% CI = 3.5% to 3.9%] vs CCI ≥ 2 = 3.4% [95% CI = 2.9% to 3.9%]); and ages 85-94 years (CCI0 = 2.7% [95% CI = 2.3% to 3.1%] vs CCI ≥ 2 = 2.1% [95% CI = 1.3% to 3.0%]). The 10-year cumulative incidence of other-cause death increased with increasing CCI and age: ages 66-74 years (CCI0 = 10.4% [95% CI = 10.3 to 10.7%] vs CCI ≥ 2 = 43.4% [95% CI = 42.2% to 44.4%]), ages 75-84 years (CCI0 = 29.8% [95% CI = 29.3% to 30.2%] vs CCI ≥ 2 = 61.7% [95% CI = 60.2% to 63.3%]), and ages 85 to 94 years (CCI0 = 60.3% [95% CI = 59.1% to 61.5%] vs CCI ≥ 2 = 84.8% [95% CI = 82.5% to 86.9%]). The 10-year cumulative incidence of breast cancer death was small and did not vary by age: ages 66-74 years = 0.2% (95% CI = 0.2% to 0.3%), ages 75-84 years = 0.29% (95% CI = 0.25% to 0.34%), and ages 85 to 94 years = 0.3% (95% CI = 0.2% to 0.4%). CONCLUSIONS: Cumulative incidence of other-cause death was many times higher than breast cancer incidence and death, depending on comorbidity and age. Hence, older women with increased comorbidity may experience diminished benefit from continued screening.
Authors: Virginia L Ernster; Rachel Ballard-Barbash; William E Barlow; Yingye Zheng; Donald L Weaver; Gary Cutter; Bonnie C Yankaskas; Robert Rosenberg; Patricia A Carney; Karla Kerlikowske; Stephen H Taplin; Nicole Urban; Berta M Geller Journal: J Natl Cancer Inst Date: 2002-10-16 Impact factor: 13.506
Authors: Shagufta Yasmeen; Rebecca A Hubbard; Patrick S Romano; Weiwei Zhu; Berta M Geller; Tracy Onega; Bonnie C Yankaskas; Diana L Miglioretti; Karla Kerlikowske Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-28 Impact factor: 4.254
Authors: Sara J T Guilcher; Aisha Lofters; Richard H Glazier; Susan B Jaglal; Jennifer Voth; Ahmed M Bayoumi Journal: Prev Med Date: 2014-07-27 Impact factor: 4.018
Authors: Shailesh Advani; Linn Abraham; Diana S M Buist; Karla Kerlikowske; Diana L Miglioretti; Brian L Sprague; Louise M Henderson; Tracy Onega; John T Schousboe; Joshua Demb; Dongyu Zhang; Louise C Walter; Christoph I Lee; Dejana Braithwaite; Ellen S O'Meara Journal: J Geriatr Oncol Date: 2021-12-09 Impact factor: 3.929
Authors: Anna-Belle Beau; George M Napolitano; Marianne Ewertz; Ilse Vejborg; Walter Schwartz; Per K Andersen; Elsebeth Lynge Journal: Cancer Med Date: 2020-04-06 Impact factor: 4.452
Authors: Pierre Fwelo; Zenab I Yusuf; Abigail Adjei; Gabriel Huynh; Xianglin L Du Journal: Breast Cancer Res Treat Date: 2022-06-24 Impact factor: 4.624
Authors: Dongyu Zhang; Linn Abraham; Joshua Demb; Diana L Miglioretti; Shailesh Advani; Brian L Sprague; Louise M Henderson; Tracy Onega; Karen J Wernli; Louise C Walter; Karla Kerlikowske; John T Schousboe; Ellen S O'Meara; Dejana Braithwaite Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-06-02 Impact factor: 4.254